Google Alert - "Myeloproliferative neoplasms" OR "polycythemia vera" OR myelofibrosis OR "essential thrombocythemia" google.com

FDA Grants Orphan Drug Designation to CK0804 in Myelofibrosis

google.com·19w

ACHILLES MSCA Network Offers PhD at Karolinska

google.com·19w

Developers Submit NDA to FDA for Rusfertide in Polycythemia Vera

google.com·19w

Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026

google.com·19w

Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis

google.com·19w

Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis

google.com·19w

NDA for Rusfertide Submitted to FDA for Polycythemia Vera

google.com·19w

FDA Application Submitted for Rusfertide Treatment in Polycythemia Vera

google.com·19w

Galecto Announces Key Additions to Leadership Team

google.com·19w

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for ...

google.com·19w

Takeda and Protagonist Therapeutics Submit NDA to FDA for Rusfertide to Treat Polycythemia Vera

google.com·19w

FDA Grants Orphan Drug Designation to Cellenkos' CK0804 Treg Therapy for Treatment of ...

google.com·19w

Doctoral theses, Master's theses and Bachelor's theses - Medizinische Hochschule Hannover

google.com·19w

Blood cancer treatments get PBAC backing

google.com·19w

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for ...

google.com·19w

Frequent and clinically relevant germline DNA repair gene variants in young and familial ...

google.com·19w

NDA Submitted to FDA for Rusfertide for Polycythemia Vera

google.com·19w

Takeda and Protagonist Announce Submission of New Drug Application for Rusfertide for ...

google.com·19w

Takeda and Protagonist Announce Submission of Rusfertide NDA for Polycythemia Vera

google.com·19w

Takeda Pharmaceutical, Protagonist Submit FDA Application for Rusfertide for Polycythemia ...

google.com·19w

Log in to enable infinite scrolling